50 patents currently held
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
2 more records may belong here and await a decision; they are not counted.
The next term ends in Oct 2032. from the record
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
0
Ending by 2030
Oct 2032
Next term end
5
Patent families
When these terms end
Held patents by the year their term ends
notable patents
all others
Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends Nov 2032 · Medium confidence
Also notable
Ends no later than Aug 2035 · Medium confidence
Also notable
Ends Nov 2032 · High confidence
Natural Combination Hormone Replacement Formulations and Therapies
US 10,806,740
Cited by 55 later US patents, top 5% of utility patents granted in 2020 in our data. Protection runs to 2032. A terminal disclaimer caps this term to an earlier patent's.
Natural Combination Hormone Replacement Formulations and Therapies
US 10,206,932
Cited by 50 later US patents, top 5% of utility patents granted in 2019 in our data, and renewed at 2 of 3 maintenance windows. Protection runs to 2035. A terminal disclaimer is on file and its reference is not resolved, so no cap is applied and the date may move earlier, never later.
Soluble Estradiol Capsule for Vaginal Insertion
US 9,180,091
Cited by 83 later US patents, top 5% of utility patents granted in 2015 in our data, and renewed at every maintenance window due so far. Protection runs to 2032. A terminal disclaimer caps this term to an earlier patent's.
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 2 fees due Feb 25, 2027
- 1 fee due Mar 3, 2027The maintenance fee for Vaginal Inserted Estradiol Pharmaceutical Compositions and Methods (US 10,398,708) comes due Mar 3, 2027. Unpaid by Sep 3, 2027, it lapses early.
- 1 fee due Apr 24, 2027The maintenance fee for Natural Combination Hormone Replacement Formulations and Therapies (US 11,793,819) comes due Apr 24, 2027. Unpaid by Oct 25, 2027, it lapses early.
- 2 fees due May 10 to 12, 2027 · next May 10
- 2 fees due Jul 9 to 21, 2027 · next Jul 9
- 1 fee due Aug 25, 2027The maintenance fee for Vaginal Inserted Estradiol Pharmaceutical Compositions and Methods (US 10,568,891) comes due Aug 25, 2027. Unpaid by Feb 25, 2028, it lapses early.
- 1 fee due Sep 22, 2027The maintenance fee for Vaginal Inserted Estradiol Pharmaceutical Compositions and Methods (US 9,289,382) comes due Sep 22, 2027. Unpaid by Mar 22, 2028, it lapses early.
- 1 fee due Oct 5, 2027The maintenance fee for Natural Combination Hormone Replacement Formulations and Therapies (US 9,301,920) comes due Oct 5, 2027. Unpaid by Apr 5, 2028, it lapses early.
- 1 fee due Nov 5, 2027The maintenance fee for Progesterone Formulations (US 10,639,375) comes due Nov 5, 2027. Unpaid by May 5, 2028, it lapses early.
Recent changes
- 1 term has ended since Aug 17, 2026
What they patent
The 4 largest of its 5 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.
| Natural Combination Hormone Replacement Formulations and Therapies (2012) | 45 in force | to Jul 2033 |
| Natural Combination Hormone Replacement Formulations and Therapies (2015) | 2 in force | to Aug 2035 |
| Mold for a Medical Dosage Form | 1 in force | to Jun 2035 |
| Steroid Hormone Pharmaceutical Formulations | 1 in force | to Nov 2032 |
Patents held now
Soonest term end first.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US D801,518 | Pharmaceutical Capsule In force · High confidence | In force | High confidence | |
| US 8,633,178 | Natural Combination Hormone Replacement Formulations and Therapies In force · High confidence | In force | High confidence | |
| US 8,846,648 | Natural Combination Hormone Replacement Formulations and Therapies In force · High confidence | In force | High confidence | |
| US 8,846,649 | Natural Combination Hormone Replacement Formulations and Therapies In force · High confidence | In force | High confidence | |
| US 8,933,059 | Natural Combination Hormone Replacement Formulations and Therapies In force · High confidence | In force | High confidence | |
| US 8,987,237 | Natural Combination Hormone Replacement Formulations and Therapies In force · High confidence | In force | High confidence | |
| US 8,987,238 | Natural Combination Hormone Replacement Formulations and Therapies In force · High confidence | In force | High confidence | |
| US 8,993,548 | Natural Combination Hormone Replacement Formulations and Therapies In force · High confidence | In force | High confidence | |
| US 8,993,549 | Natural Combination Hormone Replacement Formulations and Therapies In force · High confidence | In force | High confidence | |
| US 9,006,222 | Natural Combination Hormone Replacement Formulations and Therapies In force · High confidence | In force | High confidence |
Also on record, not counted in the 50: 10 patents ended · 7 applications pending · 35 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.